References
- Karampetsou MP, Liossis SN, Sfikakis PP. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010;103:917–928
- Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13:54–58
- Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862–2869
- Moris G. Inflammatory bowel disease: an increased risk factor for neurologic complications. World J Gastroenterol. 2014;20:1228–1237
- Solomon AJ, Spain RI, Kruer MC, Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 2011;17:1472–1487
- Leigh RJ, Zee DS. The Neurology of Eye Movements. 4th ed. Oxford: Oxford University Press, 2006
- Frohman TC, Galetta S, Fox R, et al. Pearls & oysters: The medial longitudinal fasciculus in ocular motor physiology. Neurology. 2008;70:e57–e67
- van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47:1531–1534